Hopstem Won First Place at 2024 SAPA Investment Forum & online Road Show with Innovative iPSC Cell Therapy for Chronic Stroke

Hopstem Biotechnology at 2024 CASSS CGPT Symposium

hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by FDA

hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by CFDA

The Site Initiation Visit (SIV) of the Phase 1 clinical trial on the indication of hemiplegia sequelae after chronic ischemic stroke with the hNPC01 universal cell therapy product of Hopstem Biotech was successfully held.

Hopstem Ranks on the "KPMG China's Inaugural Biotech Innovation 50 Enterprises" List

Hopstem's Founder and CEO, Dr. Jing Fan, is Listed on Forbes China's "Top 50 Women in Technology 2022"

Hopstem's Phase II GMP Cell Preparation Center Officially Inaugurated!